IMAC - IMAC initiates second cohort of Phase 1 study of mesenchymal stem cells for bradykinesia

IMAC Holdings (IMAC) has initiated the second cohort of its Phase 1 clinical trial for investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The Phase 1 trial, consisting of a 15-patient dose escalation safety and tolerability study is divided into three groups:1) five patients with bradykinesia due to Parkinson’s disease received a low dose, intravenous infusion of stem cells which was completed February 26,2) five patients will receive a medium dose intravenous infusion,3) and five patients will receive a high dose intravenous infusion. In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities.IMAC shares down 2.1% premarket at $1.86.

For further details see:

IMAC initiates second cohort of Phase 1 study of mesenchymal stem cells for bradykinesia